Drugs / Fermented Wheat Germ Extract
Fermented Wheat Germ Extract
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05967533 | Jun 2023 → Jun 2027 | colorectal carcinoma, cutaneous melanoma, female breast carcinoma, non-small cell lung carcinoma +2 | University of California, Davis | Suspended | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00411853 | Jun 2007 → Jun 2011 | hormone-resistant prostate carcinoma | Sheba Medical Center | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fermented Wheat germ extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00411853 ↗ |
| Known as | Avemar | “Combined therapy using conventional anticancer drugs and a proprietary medical nutriment, fermented wheat germ extract (FWGE), also known as Avemar, has been suggested as a...” PMID 34286638 ↗ Jul 2021 |
| Known as | FWGE | “Combined therapy using conventional anticancer drugs and a proprietary medical nutriment, fermented wheat germ extract (FWGE), also known as Avemar, has been suggested as a...” PMID 34286638 ↗ Jul 2021 |
| Action | Inhibit | “RNR enzymes, which are strongly inhibited by FWGE” NCT00411853 ↗ |
| Modality | Other / unclassified | “Fermented wheat germ extract with a standardized complex mixture of molecules is termed FWGE.” NCT00411853 ↗ |
| Route | Oral | “which administered orally” NCT00411853 ↗ |